GlassScriptPhysician profile
Jason B Wasserman
NPI 1245524370
$4,604.38
in general payments reported to CMS, 2019-2025
26 companies · $815 in 2025
The $815 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $261 · 2021: $343 · 2022: $725 · 2023: $1,133 · 2024: $842 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.05 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,045.25 | 2019-2025 | |
| Genzyme Corporation | $968.06 | 2022-2025 | |
| Glaxosmithkline, LLC. | $865.81 | 2021-2025 | Nucala |
| Stryker Corporation | $464.01 | 2019-2025 | Core, Xpress Loprofile, Entellus Medical Reinforced Anesthesia Needle |
| Regeneron Healthcare Solutions, INC. | $250.53 | 2019-2024 | Dupixent |
| Neurent Medical Limited | $198.00 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Hikma Pharmaceuticals USA | $82.34 | 2022-2024 | Ryaltris |
| Alk-Abello, INC | $73.21 | 2022-2025 | Grastek, Odactra, Ragwitek |
| Arbor Pharmaceuticals, INC. | $71.86 | 2019 | |
| Acclarent, INC | $58.80 | 2021 | |
| Kaleo, INC. | $58.78 | 2023-2024 | Auvi-Q |
| Amgen INC. | $57.83 | 2022-2023 | Tezspire |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Aerin Medical INC. | $52.48 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $49.60 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.56 | 2025 | |
| Lilly USA, LLC | $30.76 | 2025 | Zepbound |
| Medtronic USA, INC. | $29.44 | 2019 | |
| Grifols USA, LLC | $29.30 | 2025 | Xembify |
| Jazz Pharmaceuticals INC. | $24.40 | 2020 | |
| Merck Sharp & Dohme LLC | $23.75 | 2023 | |
| Medtronic, INC. | $20.35 | 2025 | Stealthstation S8 Platform |
| Inspire Medical Systems, INC. | $19.79 | 2025 | Inspire |
| Shire North American Group INC | $17.75 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Smith+Nephew, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.